Combatt DMG: Combined Anti-tumor Targeting of Diffuse Midline...

Combatt DMG: Combined Anti-tumor Targeting of Diffuse Midline Gliomas
Dr. Matthew Dun.

Is this DIPG research the "eureka moment" discovered in the Matt Dun Lab at the Hunter Medical Research Institute= Newcastle Australia

"Our pilot data showed high-level synergistic cell death in 88% of DMG cell lines when treated with PI3K inhibitors in combination with PKC inhibitors, FDA approved to treat other cancers.."

https://thecurestartsnow.org/impact/research-and-grants/hunter-medical-research-institute-145-640/

Thank you Lab Man - posted on **promotion blocked** - $KZIA.

Breakthrough new research which strongly supports belief this is a multi billion dollar drug. Studies here from Dr Matt Dun, Sydney who has worked closely with the company. These studies will soon lead to a new clinical trial in DMG (DIPG). OS & ORR. Profiling the activity of proteins (phosphoproteomics) in DMG tumor cells following treatment with paxalisib, identified that the tumor amplified communication (Protein kinase C - PKC) pathways that activate migratory and infiltrative growth dissemination (‘diffuse’/’intrinsic’, hallmarks of DMG). These finding led us to test the hypothesis that dual targeting of PI3K/Akt/mTOR and PKC has the potential to improve outcomes for DMG patients by stopping proliferative and infiltrative growth.Our pilot data showed high-level synergistic cell death in 88% of DMG cell lines when treated with PI3K inhibitors in combination with PKC inhibitors.

Regards.